Drugs for aki
Pro Research Analysisby 
Searched over 200M research papers
Drugs for Acute Kidney Injury (AKI): Current Research and Developments
Introduction to Acute Kidney Injury (AKI)
Acute Kidney Injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. It causes waste products to build up in the blood and makes it hard for the kidneys to maintain the right balance of fluid in the body. AKI can also affect other organs such as the brain, heart, and lungs.
Promising Drug Targets and Mechanisms
Mitochondrial Dysfunction and New Drug Targets
Recent advancements have identified mitochondrial dysfunction as a critical factor in AKI, leading to the development of new drug targets. These targets have transformed the therapeutic landscape, offering hope for effective treatments .
Tetramethylpyrazine (TMP)
Tetramethylpyrazine (TMP), an active ingredient in the Chinese herb Ligusticum wallichii, has shown promise in preventing AKI. TMP works by reducing oxidative stress, inhibiting inflammation, preventing apoptosis of renal cells, and regulating autophagy. This compound also has potential in preventing the progression of chronic kidney disease (CKD) .
SS31 Prodrug
The SS31 prodrug, which targets mitochondria, has shown effectiveness in AKI therapy by rapidly distributing in the kidney and retaining in the renal tubules. This drug reduces oxidative stress, inflammation, and cell apoptosis, thereby protecting the kidneys from damage .
Antiferroptosis Agents
Ferroptosis, a type of cell death driven by lipid peroxidation, is a significant contributor to AKI. Drugs that act as lipid peroxyl radical scavengers, such as rifampicin, promethazine, and omeprazole, have been identified as potential antiferroptosis agents. These drugs have shown efficacy in reducing organ damage, including AKI, by scavenging lipid peroxyl radicals .
0-Dimensional Nanodrugs
0-Dimensional (0D) antioxidant nanodrugs have emerged as a novel approach to AKI treatment. These nanodrugs exhibit high performance due to their small size, multi-antioxidant enzyme mimetic activities, and excellent biocompatibility. They overcome renal physiological barriers and offer a promising solution for AKI antioxidant therapy .
Risks and Benefits of Drug Use in AKI
Drug-Induced AKI
Certain drug classes are frequently implicated in causing AKI. Antibacterial agents, diuretics, agents acting on the renin-angiotensin system, antineoplastic agents, and anti-inflammatory agents are among the most common culprits. Drugs such as gentamicin, eplerenone, spironolactone, and cisplatin have high reporting odds ratios for inducing AKI .
Temporary Discontinuation of Medications
Temporary discontinuation of medications like ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) before procedures such as coronary angiography and cardiac surgery may reduce the incidence of AKI. However, the evidence is of low quality, and further research is needed to confirm these findings .
NSAIDs and AKI Risk
Non-steroidal anti-inflammatory drugs (NSAIDs) are well-known for their association with AKI. The risk is particularly high when NSAIDs are used in combination with diuretics and renin-angiotensin system inhibitors. This combination significantly increases the incidence of AKI, especially in older adults and those with pre-existing renal impairment Ungprasert2015Dreischulte2015.
Conclusion
The field of AKI treatment is evolving with the identification of new drug targets and mechanisms. Compounds like TMP, SS31 prodrug, and 0D nanodrugs offer promising therapeutic options. However, the risk of drug-induced AKI remains a significant concern, necessitating careful consideration of medication use, especially in vulnerable populations. Further research is essential to develop safe and effective treatments for AKI.
Sources and full results
Most relevant research papers on this topic